Ulrike Bauder-Wust
Heidelberg, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Investigation of Radiolabeled KISS1R Ligands as Promising Tools for Diagnosis and Treatment of Triple-Negative Breast Cancer.
Journal: Molecular pharmaceutics
Published: March 03, 2026
Differential Radiobiological Effects of Αlpha- and Beta-Minus-Emitter Targeted Radionuclide Therapy: DNA Damage and Survival.
Journal: International journal of radiation oncology, biology, physics
Published: January 15, 2026
EpCAM-PSMA: Potential predictors of treatment outcomes for PSMA-targeted alpha therapies in metastatic castration-resistant prostate cancer.
Journal: Molecular therapy. Oncology
Published: November 18, 2025
Genomic analysis in chemotherapy-naïve prostate cancer prior to PSMA-targeted treatment.
Journal: Frontiers in oncology
Published: November 06, 2025
Exploratory case series of circulating tumor DNA dynamics during tandem therapy in metastatic castration-resistant prostate cancer.
Journal: EJNMMI research
Published: October 02, 2025
Synthesis and Preclinical Evaluation of a Bispecific PSMA-617/RM2 Heterodimer Targeting Prostate Cancer.
Journal: ACS medicinal chemistry letters
Published: August 11, 2024
Human ABC and SLC Transporters: The Culprit Responsible for Unspecific PSMA-617 Uptake?
Journal: Pharmaceuticals (Basel, Switzerland)
Published: March 07, 2024
Synthesis of tritium-labeled Lu-PSMA-617: Alternative tool for biological evaluation of radiometal-based pharmaceuticals.
Journal: Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
Published: January 31, 2023
Investigation of Tumor Cells and Receptor-Ligand Simulation Models for the Development of PET Imaging Probes Targeting PSMA and GRPR and a Possible Crosstalk between the Two Receptors.
Journal: Molecular pharmaceutics
Published: April 25, 2022
Refined Chelator Spacer Moieties Ameliorate the Pharmacokinetics of PSMA-617.
Journal: Frontiers in chemistry
Published: March 17, 2022
A New Class of PSMA-617-Based Hybrid Molecules for Preoperative Imaging and Intraoperative Fluorescence Navigation of Prostate Cancer.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: December 22, 2021
Last Updated: 09/26/2026